Mar 28 |
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
|
Mar 28 |
Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope
|
Mar 28 |
Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
|
Mar 26 |
FDA grants priority review for Syndax leukemia drug, sets action date
|
Mar 26 |
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
|
Mar 18 |
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
|
Mar 13 |
Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation
|